Raloxifene (Evista): Uses, Benefits, and Safety Profile
Raloxifene is a selective estrogen receptor modulator (SERM) with tissue-specific estrogen agonist/antagonist effects.
FDA-Approved Indications
1. Osteoporosis Prevention/Treatment in Postmenopausal Women: Agonist at bone ER → maintains BMD, reduces vertebral fracture risk ~30–50%. No significant effect on non-vertebral/hip fractures.
2. Breast Cancer Risk Reduction: Antagonist at breast ER → reduces invasive ER+ breast cancer incidence by ~50–76% in high-risk postmenopausal women (STAR trial vs. tamoxifen). Not for treatment of existing breast cancer.
Additional Effects
- Lipids: Lowers total and LDL cholesterol (~10–12%); minimal effect on HDL, triglycerides.
- Coagulation: No increase in VTE risk vs. placebo in osteoporosis trials, but contraindicated with history of VTE.
- Endometrium: Neutral (no hyperplasia risk vs. tamoxifen).
- Hot flashes: May worsen; not indicated for vasomotor symptoms.
Contraindications & Precautions
- History of VTE (DVT, PE, retinal vein thrombosis)
- Active or recent major surgery with immobilization
- Pregnancy (Category X)
- Severe hepatic impairment
- Unexplained uterine bleeding
Monitoring
BMD q1–2 years. Clinical breast exams, mammograms per guidelines. No routine endometrial surveillance needed. Counsel on VTE symptoms (calf pain, dyspnea) and stroke signs.
Prescription Medications - Related Articles
- Motrin & Blood Pressure: A Comprehensive Guide for Safe Use
- Ritalin (Methylphenidate): Side Effects, Risks, and Monitoring
- Anticonvulsants and GABA Levels: Understanding the Connection
- Namenda (Memantine): Understanding Risks, Side Effects & Interactions
- Zometa (Zoledronic Acid): Uses, Side Effects & Information
- Understanding Ritalin Strengths: Dosage, Formulations & Uses
- Medical Uses of Opioids: Indications, Mechanisms & Risk Mitigation
